Ad26.Filo — Competitive Intelligence Brief

Ad26.Filo (Ad26.Filo) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Infectious Disease.

phase 1 Viral vector vaccine Filovirus glycoprotein Infectious Disease Biologic

Target snapshot

Ad26.Filo (Ad26.Filo) — Janssen Vaccines & Prevention B.V.. Ad26.Filo is a viral vector vaccine that targets filoviruses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ad26.Filo TARGET	Ad26.Filo	Janssen Vaccines & Prevention B.V.	phase 1	Viral vector vaccine	Filovirus glycoprotein
MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]	MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]	Janssen Vaccines & Prevention B.V.	phase 3	Recombinant viral vector vaccine	Filovirus glycoproteins (Ebola virus GP, Marburg virus GP)
MVA-BN-Filo 5*10^7 Inf. U.	MVA-BN-Filo 5*10^7 Inf. U.	Janssen Vaccines & Prevention B.V.	phase 3	Viral vector vaccine	Filovirus glycoproteins (Ebola virus GP, Marburg virus GP)
batch 3 of Ad5-nCoV	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
rVSV∆G-ZEBOV-GP	rVSV∆G-ZEBOV-GP	University of Birmingham	marketed	Live attenuated viral vector vaccine	Zaire ebolavirus glycoprotein (EBOV-GP)
Intramuscularly administered Ad5-nCoV vaccine	Intramuscularly administered Ad5-nCoV vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

1. Janssen Vaccines & Prevention B.V. · 5 drugs in this class
2. University of Oxford · 3 drugs in this class
3. Crucell Holland BV · 3 drugs in this class
4. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
5. Bharat Biotech International Limited · 2 drugs in this class
6. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
7. London School of Hygiene and Tropical Medicine · 1 drug in this class
8. Samia Hassan El-Shishtawy · 1 drug in this class
9. University Medicine Greifswald · 1 drug in this class
10. Aeras · 1 drug in this class